ABVC BioPharma, Inc.
ABVC
$0.96
-$0.10-9.52%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -796.00K | 796.00K | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -796.00K | 796.00K | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -796.00K | 796.00K | -- |
| SG&A Expenses | 756.80K | 1.54M | 2.17M | 1.93M | 2.26M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -3.50K | -2.20K | -- |
| Total Operating Expenses | 779.50K | 1.57M | 2.20M | 1.96M | 2.30M |
| Operating Income | -779.50K | -1.57M | -2.99M | -1.17M | -2.30M |
| Income Before Tax | -810.50K | -1.69M | -3.81M | -1.29M | -2.31M |
| Income Tax Expenses | -- | -- | 0.00 | 500.00 | 23.60K |
| Earnings from Continuing Operations | -810.50K | -1.69M | -3.81M | -1.29M | -2.33M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 73.50K | 129.70K | 249.50K | 41.00K | 75.80K |
| Net Income | -736.90K | -1.56M | -3.56M | -1.25M | -2.26M |
| EBIT | -779.50K | -1.57M | -2.99M | -1.17M | -2.30M |
| EBITDA | -773.00K | -1.57M | -2.99M | -1.16M | -2.29M |
| EPS Basic | -0.03 | -0.06 | -0.14 | -0.05 | -0.13 |
| Normalized Basic EPS | -0.02 | -0.04 | -0.06 | -0.03 | -0.08 |
| EPS Diluted | -0.03 | -0.06 | -0.15 | -0.05 | -0.13 |
| Normalized Diluted EPS | -0.02 | -0.04 | -0.06 | -0.03 | -0.08 |
| Average Basic Shares Outstanding | 26.06M | 25.45M | 24.73M | 23.26M | 17.39M |
| Average Diluted Shares Outstanding | 26.06M | 25.45M | 24.73M | 23.26M | 17.39M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |